



PATENT  
Attorney Docket No. P05779US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: LIU, et al.  
SERIAL NO: 10643829  
FILED: August 19, 2003  
TITLE: OVARIAN CANCER-SPECIFIC PROMOTER

Group Art Unit:  
Examiner:

Confirmation No:

**INFORMATION DISCLOSURE STATEMENT  
FILED WITHIN THREE MONTHS OF FILING OR  
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. § 1.97(b))**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This information disclosure statement is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits, or before the mailing of a first office action after the filing of a request for continued examination, whichever event occurs last.

Applicant discloses herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose. Legible copies of all items listed in Forms PTO/SB/08A and 08B (formerly Form PTO-1449) accompany this information statement..

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the

=====

**CERTIFICATE OF MAILING/TRANSMISSION (37 CFR 1.8(a))**

I hereby certify that this correspondence is, on the date shown below, being:

**MAILING**

deposited with the United States Postal Service with sufficient postage as First Class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 10/19/03

**FACSIMILE**


transmitted by facsimile to the Patent and Trademark Office, Art Unit \_\_\_\_\_ at Fax No. (703) 872-\_\_\_\_\_.

  
HEIDI S. NEBEL

information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner.

Respectfully submitted,



HEIDI S. NEBEL, Reg. No. 37,719  
McKEE, VOORHEES & SEASE, P.L.C.  
801 Grand Avenue, Suite 3200  
Des Moines, Iowa 50309-2721  
Phone No. (515) 288-3667  
Fax No. (515) 288-1338  
**CUSTOMER NO: 22885**

- mlw -

Attorneys of Record



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Application Number</b> <input type="text"/> <b>Filing Date</b> <input type="text"/> <b>First Named Inventor</b> LIU, et al. <b>Group Art Unit</b> <input type="text"/> <b>Examiner Name</b> <input type="text"/> <b>Attorney Docket Number</b> P05779US1	
Sheet	1	of	1		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	1	ROBERT C. BAST, et al., Reactivity of a Monoclonal Antibody with Human Ovarian Carcinoma, J. Clin. Invest., Volume 68, November 1981, 1331-1337		
	2	THOMAS L. KLUG, et al., Monoclonal Antibody Immunoassay for an Antigenic Determinant (CA 125) Associated with Human Epithelial Ovarian Carcinomas, Cancer Research 44, 1048-1053, March 1984		
	3	GIJSBERT G. BON, et al., Serum tumor marker immunoassays in gynecologic oncology: Establishment of reference values, Am J Obstet Gynecol 1996; 174:107-14.		
	4	K. NUSTAD, et al., CA 125 – epitopes and molecular size, The International Journal of Biological Markers, Vol. 13 No.4, pp. 196-199, 1998		
	5	IAN G. CAMPBELL, et al., A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1, Human Molecular Genetics, 1994, Vol. 3, No. 4, 589-594		
	6	CAROLINE WHITEHOUSE, et al., NBR1 interacts with fasciculation and elongation protein zeta-1 (FEZ1) and calcium and integrin binding protein (CIB) and shows developmentally restricted expression in the neural tube, Eur. J. Biochem. 269, 538-545 (2002)		
	7	BEATRICE W. T. YIN and KENNETH O. LLOYD, Molecular Cloning of the CA125 Ovarian Cancer Antigen, The Journal of Biological Chemistry, Vol. 276, No. 29, Issue of July 20, pp. 27371-27375, 2001		
	8	TIMOTHY J. O'BRIEN et al., The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences, Tumor Biol 2001; 22:348-366		
	9	WILLIAM H. KUTTEH, et al., Immunologic Characterization of Tumor Markers in Human Ovarian Cancer Cell Lines, J Soc Gynecol Invest 1996; 3:216-22		
	10	CAROLINE WHITEHOUSE and ELLEN SOLOMON, Current Status of the Molecular Characterization of the Ovarian Cancer Antigen CA125 and Implications for Its Use in Clinical Screening, Gynecologic Oncology 88, S152-S157 (2003)		
	11	STOIL DIMITROV et al., Expression profiles and intergenic structure of head-to-head oriented <i>Brca1</i> and <i>Nbr1</i> genes, Gene 262 (2001) 89-98		
	12	KATSUYUKI HAMADA et al., Identification of the Human IAI.3B Promoter Element and Its Use in the Construction of a Replication-selective Adenovirus for Ovarian Cancer Therapy, Cancer Research 63, 2506-2512, May 15, 2003		

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.